Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug

Abstract Camptothecin (CPT) is an anti-cancer drug that effectively treats various cancers, including colon cancer. However, poor solubility and other drawbacks have restricted its chemotherapeutic potential. To overcome these restrictions, CPT was encapsulated in CEF (cyclodextrin-EDTA-FE3O4), a co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Poorani Krishnan, Mariappan Rajan, Sharmilah Kumari, S. Sakinah, Sivan Padma Priya, Fatin Amira, Lawal Danjuma, Mok Pooi Ling, Sharida Fakurazi, Palanisamy Arulselvan, Akon Higuchi, Ramitha Arumugam, Abdullah A. Alarfaj, Murugan A. Munusamy, Rukman Awang Hamat, Giovanni Benelli, Kadarkarai Murugan, S. Suresh Kumar
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fd17cfce15764f71a8324eb089ef8a94
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd17cfce15764f71a8324eb089ef8a94
record_format	dspace
spelling	oai:doaj.org-article:fd17cfce15764f71a8324eb089ef8a942021-12-02T15:05:34ZEfficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug10.1038/s41598-017-09140-12045-2322https://doaj.org/article/fd17cfce15764f71a8324eb089ef8a942017-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09140-1https://doaj.org/toc/2045-2322Abstract Camptothecin (CPT) is an anti-cancer drug that effectively treats various cancers, including colon cancer. However, poor solubility and other drawbacks have restricted its chemotherapeutic potential. To overcome these restrictions, CPT was encapsulated in CEF (cyclodextrin-EDTA-FE3O4), a composite nanoparticle of magnetic iron oxide (Fe3O4), and β-cyclodextrin was cross-linked with ethylenediaminetetraacetic acid (EDTA). This formulation improved CPT’s solubility and bioavailability for cancer cells. The use of magnetically responsive anti-cancer formulation is highly advantageous in cancer chemotherapy. The chemical characterisation of CPT-CEF was studied here. The ability of this nano-compound to induce apoptosis in HT29 colon cancer cells and A549 lung cancer cells was evaluated. The dose-dependent cytotoxicity of CPT-CEF was shown using MTT. Propidium iodide and Annexin V staining, mitochondrial membrane depolarisation (JC-1 dye), and caspase-3 activity were assayed to detect apoptosis in CPT-CEF-treated cancer cells. Cell cycle analysis also showed G1 phase arrest, which indicated possible synergistic effects of the nano-carrier. These study results show that CPT-CEF causes a dose-dependent cell viability reduction in HT29 and A549 cells and induces apoptosis in colon cancer cells via caspase-3 activation. These data strongly suggest that CPT could be used as a major nanocarrier for CPT to effectively treat colon cancer.Poorani KrishnanMariappan RajanSharmilah KumariS. SakinahSivan Padma PriyaFatin AmiraLawal DanjumaMok Pooi LingSharida FakuraziPalanisamy ArulselvanAkon HiguchiRamitha ArumugamAbdullah A. AlarfajMurugan A. MunusamyRukman Awang HamatGiovanni BenelliKadarkarai MuruganS. Suresh KumarNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-16 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Poorani Krishnan Mariappan Rajan Sharmilah Kumari S. Sakinah Sivan Padma Priya Fatin Amira Lawal Danjuma Mok Pooi Ling Sharida Fakurazi Palanisamy Arulselvan Akon Higuchi Ramitha Arumugam Abdullah A. Alarfaj Murugan A. Munusamy Rukman Awang Hamat Giovanni Benelli Kadarkarai Murugan S. Suresh Kumar Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug
description	Abstract Camptothecin (CPT) is an anti-cancer drug that effectively treats various cancers, including colon cancer. However, poor solubility and other drawbacks have restricted its chemotherapeutic potential. To overcome these restrictions, CPT was encapsulated in CEF (cyclodextrin-EDTA-FE3O4), a composite nanoparticle of magnetic iron oxide (Fe3O4), and β-cyclodextrin was cross-linked with ethylenediaminetetraacetic acid (EDTA). This formulation improved CPT’s solubility and bioavailability for cancer cells. The use of magnetically responsive anti-cancer formulation is highly advantageous in cancer chemotherapy. The chemical characterisation of CPT-CEF was studied here. The ability of this nano-compound to induce apoptosis in HT29 colon cancer cells and A549 lung cancer cells was evaluated. The dose-dependent cytotoxicity of CPT-CEF was shown using MTT. Propidium iodide and Annexin V staining, mitochondrial membrane depolarisation (JC-1 dye), and caspase-3 activity were assayed to detect apoptosis in CPT-CEF-treated cancer cells. Cell cycle analysis also showed G1 phase arrest, which indicated possible synergistic effects of the nano-carrier. These study results show that CPT-CEF causes a dose-dependent cell viability reduction in HT29 and A549 cells and induces apoptosis in colon cancer cells via caspase-3 activation. These data strongly suggest that CPT could be used as a major nanocarrier for CPT to effectively treat colon cancer.
format	article
author	Poorani Krishnan Mariappan Rajan Sharmilah Kumari S. Sakinah Sivan Padma Priya Fatin Amira Lawal Danjuma Mok Pooi Ling Sharida Fakurazi Palanisamy Arulselvan Akon Higuchi Ramitha Arumugam Abdullah A. Alarfaj Murugan A. Munusamy Rukman Awang Hamat Giovanni Benelli Kadarkarai Murugan S. Suresh Kumar
author_facet	Poorani Krishnan Mariappan Rajan Sharmilah Kumari S. Sakinah Sivan Padma Priya Fatin Amira Lawal Danjuma Mok Pooi Ling Sharida Fakurazi Palanisamy Arulselvan Akon Higuchi Ramitha Arumugam Abdullah A. Alarfaj Murugan A. Munusamy Rukman Awang Hamat Giovanni Benelli Kadarkarai Murugan S. Suresh Kumar
author_sort	Poorani Krishnan
title	Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug
title_short	Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug
title_full	Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug
title_fullStr	Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug
title_full_unstemmed	Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug
title_sort	efficiency of newly formulated camptothecin with β-cyclodextrin-edta-fe3o4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (ht29) drug
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/fd17cfce15764f71a8324eb089ef8a94
work_keys_str_mv	AT pooranikrishnan efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT mariappanrajan efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT sharmilahkumari efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT ssakinah efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT sivanpadmapriya efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT fatinamira efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT lawaldanjuma efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT mokpooiling efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT sharidafakurazi efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT palanisamyarulselvan efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT akonhiguchi efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT ramithaarumugam efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT abdullahaalarfaj efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT muruganamunusamy efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT rukmanawanghamat efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT giovannibenelli efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT kadarkaraimurugan efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug AT ssureshkumar efficiencyofnewlyformulatedcamptothecinwithbcyclodextrinedtafe3o4nanoparticleconjugatednanocarriersasananticoloncancerht29drug
_version_	1718388807604109312

Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug

Ejemplares similares